These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 22236405)

  • 1. Predicted deleterious variants in ABCA1, LPL, LPA and KIF6 are associated with statin response and adverse events in patients with familial hypercholesterolemia and disturb protein structure and stability.
    Dagli-Hernandez C; Ferreira GM; Freitas RCC; Borges JB; Oliveira VF; Gonçalves RM; Faludi AA; Marçal EDSR; Bastos GM; Bortolin RH; Hirata MH; Hirata RDC
    Pharmacogenet Genomics; 2024 Jun; 34(4):91-104. PubMed ID: 38682317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could siRNA therapeutics change the way we treat dyslipidemia?
    Penson PE; McCloskey AP
    Expert Opin Biol Ther; 2024 May; 24(5):315-316. PubMed ID: 38770967
    [No Abstract]   [Full Text] [Related]  

  • 3. Case Response III.
    Bovensiepen G
    J Anal Psychol; 2024 Sep; 69(4):678-681. PubMed ID: 39078317
    [No Abstract]   [Full Text] [Related]  

  • 4. The Effect of a Persian Herbal Medicine Compound on the Lipid Profiles of Patients with Dyslipidemia: A Randomized Double-Blind Placebo-Controlled Clinical Trial.
    Niknafs A; Rezvanfar M; Kamalinejad M; Latifi SA; Almasi-Hashiani A; Salehi M
    Evid Based Complement Alternat Med; 2021; 2021():6631963. PubMed ID: 34104201
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Chen Q; Ji C; Zheng R; Yang L; Ren J; Li Y; Han Y; Zhou P; Liu Z; Qiu Y
    Front Pharmacol; 2019; 10():1622. PubMed ID: 32047441
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mangiferin supplementation improves serum lipid profiles in overweight patients with hyperlipidemia: a double-blind randomized controlled trial.
    Na L; Zhang Q; Jiang S; Du S; Zhang W; Li Y; Sun C; Niu Y
    Sci Rep; 2015 May; 5():10344. PubMed ID: 25989216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of multiple association studies provides evidence of an expression QTL hub in gene-gene interaction network affecting HDL cholesterol levels.
    Ma L; Ballantyne C; Brautbar A; Keinan A
    PLoS One; 2014; 9(3):e92469. PubMed ID: 24651390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
    Brautbar A; Barbalic M; Chen F; Belmont J; Virani SS; Scherer S; Hegele RA; Ballantyne CM
    J Lipid Res; 2013 Jul; 54(7):1980-7. PubMed ID: 23633496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic determinants of cardiometabolic risk: a proposed model for phenotype association and interaction.
    Blackett PR; Sanghera DK
    J Clin Lipidol; 2013; 7(1):65-81. PubMed ID: 23351585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Covarrubias D; Belmont J; Lara-Garduno F; Virani SS; Jones PH; Leal SM; Ballantyne CM
    Atherosclerosis; 2011 Dec; 219(2):737-42. PubMed ID: 21889769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
    Ma L; Ballantyne CM; Belmont JW; Keinan A; Brautbar A
    J Lipid Res; 2012 Nov; 53(11):2425-8. PubMed ID: 22896670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.
    Campbell J; Mohiuddin SM
    Drugs Today (Barc); 2010 Oct; 46(10):757-64. PubMed ID: 21076712
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.
    Moutzouri E; Kei A; Elisaf MS; Milionis HJ
    Vasc Health Risk Manag; 2010 Aug; 6():525-39. PubMed ID: 20730069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.
    Brautbar A; Virani SS; Belmont J; Nambi V; Jones PH; Ballantyne CM
    J Lipid Res; 2012 Mar; 53(3):556-560. PubMed ID: 22236405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemia.
    Gao F; Ballantyne C; Ma L; Virani SS; Keinan A; Brautbar A
    Atherosclerosis; 2014 Jun; 234(2):249-53. PubMed ID: 24704626
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.